|
GSK
Ebola vaccine fast-tracked into U.S., UK and African trials
Send a link to a friend
[August 28, 2014] LONDON
(Reuters) - An experimental Ebola vaccine from GlaxoSmithKline is being
fast-tracked into human studies and the company plans to build up a
stockpile of up to 10,000 doses for emergency deployment, if results are
good.
|
|
 Britain's biggest drugmaker said on Thursday the research was being
accelerated with funding from an international consortium,
reflecting mounting concern over the worst-ever outbreak of the
disease in West Africa that has killed more than 1,500 people.
The candidate vaccine, which is being co-developed with the U.S.
National Institutes of Health (NIH), is expected to be given to
healthy volunteers in Britain and the United States from around
mid-September, with the program then being extended to volunteers in
Gambia and Mali.
(Reporting by Ben Hirschler, Editing by Paul Sandle)
[to top of second column] |
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
